Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (3674)	1/27/1998 12:16:00 AM
From: JOHN W.	Respond to of 6136

"Green Cross Scraps Gene Therapy Plan for HIV Patients" Kyodo News Service (01/26/98) Green Cross Corp., a Japanese pharmaceutical company, has said it will drop its plans to test a gene therapy treatment on people with HIV. However, research will still continue on the treatment. The company decided to abandon the plan due to the lack of available reports on the effectiveness of similar trials on 200 HIV-positive patients in the United States. Green Cross initially planned to test the gene treatment on four HIV-positive individuals at the Kumamoto University Hospital in southwestern Japan, using a specially created vector to introduce a gene designed to activate patients' HIV-fighting T-cells to prevent the development of AIDS. The four prospective patients had consented to the test, and the Japanese government had approved the trials in May 1997.